TENNCT06119490
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 17 words Show 6 more changesShow less
- Trial status changed: Unknown → Completed
- Final enrollment: 18 participants (planned 30)
- Primary completion date changed from estimate of Jul 2026 to Oct 14, 2025
- Study completion date changed from estimate of Sep 2026 to Nov 9, 2025
- Secondary endpoints: details revised at 1 of 1 entry
- Site details revised
- Minor Changed Registry marked status Unknown; last known: Recruiting
- Minor Interventions: Abrocitinib (Drug) to Abrocitinib (Drug), Tofacitinib (Drug)
- Study arms: 1 to 2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time to Reepithelization
Timeframe: up to 8 week
Secondary (1)
Adverse events
Arms and interventions
Arocitinib-armOther
Evaluation of the efficacy and safety of methylprednisolone combined with abrocitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with Arocitinib 200 mg daily.
Tofacitinib-armOther
Evaluation of the efficacy and safety of methylprednisolone combined with tofacitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with tofacitinib 10 mg daily.
Drugs: Abrocitinib, Tofacitinib
Sites
1 site in 1 country
- Department of Dermatology, the First Affiliated Hospital of Fujian Medical University.Fuzhou, Fujian, China